Working with life sciences companies, David has developed and reviewed financial projections, determined fair market value for products and services subject to anti-kickback and other health care regulatory compliance issues, valued licensing agreements and other contingent payments, benchmarked potential licensing terms, valued preferred and common stock and valued employee stock options.
David also has prior experience in building financial and operational models. His areas of expertise include statistical analysis, stock price and options modeling, developing commodity supply and price forecasts, building probabilistic models and decision trees, quantifying risk and analysis of market data.
David received a Ph.D. in neuroscience from Stanford University and a B.S. in biology from Massachusetts Institute of Technology.
